BioMarin Awaits EU Drug Regulator Review
by Bloomberg Industries
BioMarin’s Vimizim (GALNS, elosulfase alfa) enzyme replacement therapy for the treatment of Mucopolysaccharidosis (MPS) Type IVA (Morquio A syndrome) is among drugs expected to receive an opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) during its February meeting. Decisions are expected on Feb. 20 or 21. Morquio A syndrome is a rare genetic disease that causes a buildup of keratan sulfate in tissues and organs.